MAP2K1 and cancer: Furthermore, studies suggest RAMP1 as a biomarker for tumorigenesis, impacting the MAP2KI (MEK1) signaling pathway (mitogen-activated protein kinase signaling pathway 2) (Logan et al., 2013) and its association with neuronal nociceptors and cancer disease progression (Balood et al., 2022).